Exogenous IL-4 and IL-13 enhanced the growth of pancreatic cancer cells in a dose-dependent manner [25,26], which was inhibited by IL-4-/IL-13-neutralizing antibodies. This evidence concerns the gene IL13 and familial pancreatic carcinoma.